Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 20 recruiting now early-phase tilt

HIV Prevention: early-phase trial registry

20 of 33 indexed HIV Prevention trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #463 of 28,707 conditions by registered trial count.

33 US clinical trials · 20 currently recruiting · #463 of 28,707 conditions by registered trial count

HIV Prevention: 33 US clinical trials tracked, 20 recruiting.

HIV Prevention is the subject of 33 registered US clinical trials on ClinicalTrials.gov, 20 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Johns Hopkins University, running 3 of these trials.

Enrollment posture brief

Registry condition hiv-prevention

OPEN 20 | RECR 61% | LATE 2 | EARLY 4 | RANK #463 | SPON 3

Nearest open-share peer: Metastatic Breast Carcinoma (61% recruiting · 33 trials)

HIV Prevention (this)61%Barrett Esophagus54.5%Clinical Stage IV Cutaneous 45.5%Child Development39.4%Anatomic Stage IIB Breast Ca24.2%
Open-enrollment share among volume-matched conditions near HIV Prevention

HIV Prevention lists 20 open slots (61% of 33 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for HIV Prevention on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. HIV Prevention is recruiting above its size-band peers.

    20 of 33 indexed trials (60.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of HIV Prevention trials is spread across many organizations.

    Johns Hopkins University accounts for 3 of 33 trials (9.1%). 23 distinct sponsors appear on at least one study for this condition label.

  3. Typical HIV Prevention enrolment sits around 101 participants.

    Median target enrolment is 101 among the 33 trials that report a genuine target (sentinel values excluded). 13 of those (39.4%) plan for fewer than 100 participants.

  4. HIV Prevention research is mostly interventional.

    28 interventional and 5 observational studies make up this index (84.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 21Phase 42

Open and recent trials

33 total, page 1 of 1

RECRUITING NA 5,100 participants

Digital Limited Interaction Efficacy Trial of LifeSkills Mobile to Reduce HIV Incidence in YTW

University of California, Los Angeles

NCT05018611

RECRUITING NA 1,000 participants

Using PrEP, Doing It for Ourselves

Duke University

NCT06638892

RECRUITING NA 600 participants

Suubi4PrEP: Improving PrEP Access and Adherence Among Adolescent Girls and Young Women in Uganda

Washington University School of Medicine

NCT07002866

RECRUITING NA 458 participants

Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program

University of Washington

NCT05856942

RECRUITING NA 350 participants

Client-Centered Care Coordination for Black Men Who Have Sex With Men

University of Maryland, Baltimore

NCT06056544

RECRUITING NA 318 participants

California MEPS Hub

University of California, Los Angeles

NCT07433985

RECRUITING NA 300 participants

Intervention to Enhance PrEP Persistence

Brown University

NCT06872307

RECRUITING NA 300 participants

A Multi-Level Trauma-Informed Approach to Increase HIV Pre-exposure Prophylaxis Initiation Among Black Women

Johns Hopkins Bloomberg School of Public Health

NCT06703060

RECRUITING NA 200 participants

Testing a Gender-inclusive HIV Prevention Program

Center for Innovative Public Health Research

NCT06586151

RECRUITING NA 175 participants

Stick2PrEP Cisgender Women and Trans Individuals

Columbia University

NCT05165745

RECRUITING 150 participants

HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots

University of Colorado, Denver

NCT04979728

RECRUITING 100 participants

The Unlocking PrEP Study: Integration of Peer Health Navigation Into Comprehensive Re-entry Services

University of Texas Southwestern Medical Center

NCT07292792

RECRUITING Phase 4 100 participants

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

Duke University

NCT07218211

RECRUITING NA 100 participants

Safe Spaces 4 Sexual Health

Johns Hopkins University

NCT07133555

RECRUITING NA 75 participants

WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women

University of Colorado, Denver

NCT06656676

RECRUITING NA 66 participants

An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South

Rhode Island Hospital

NCT05087680

RECRUITING NA 60 participants

Behavioral Economic Intervention to Improve HIV Behaviors in Sexual Minority Individuals

The University of Texas Health Science Center at San Antonio

NCT06745947

RECRUITING NA 56 participants

PrOTECT AL: PrEP Optimization Through Enhanced Continuum Tracking

University of Alabama at Birmingham

NCT07231640

RECRUITING NA 40 participants

Prepping for The Talk: Helping Trusted Adults and Youth Talk About Sexual Health

Rhode Island Hospital

NCT07011563

RECRUITING Phase 1 24 participants

Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

Johns Hopkins University

NCT07349758

ACTIVE NOT RECRUITING NA 1,170 participants

Clinic-based HIV Identification and Prevention Project Using Electronic Resources

Johns Hopkins University

NCT05412433

ACTIVE NOT RECRUITING NA 446 participants

Integrated HIV Prevention and HCV Care for PWID

Columbia University

NCT03981445

ACTIVE NOT RECRUITING NA 239 participants

PrEP Affect Regulation Treatment Innovation

Florida International University

NCT04899024

COMPLETED Phase 2 304 participants

Pre-Exposure Prophylaxis for Transgender Women in the US and South America

HIV Prevention Trials Network

NCT04742491

COMPLETED NA 125 participants

Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use

University of Washington

NCT03112369

COMPLETED Phase 1 101 participants

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

CONRAD

NCT01813162

COMPLETED NA 72 participants

Addressing Health Disparities in Engagement, Retention, and Utilization of PrEP Among South Florida Women of Color

Florida International University

NCT05338996

COMPLETED 69 participants

Implantable Long-Acting Pre-Exposure Prophylaxis For MSM

Elizabeth Arnold

NCT05420207

COMPLETED 40 participants

Biomarkers of Protocol Compliance and Product Adherence

CONRAD

NCT01804023

COMPLETED 31 participants

Study for IFE4PrEP Intervention on PrEP Uptake by Southern African American Women

University of North Carolina, Chapel Hill

NCT05087927

COMPLETED NA 21 participants

Formative Research for an HIV Videogame for Young Black Women

Yale University

NCT02685410

COMPLETED Phase 4 20 participants

DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence

Public Health Foundation Enterprises

NCT03387462

COMPLETED Phase 1 9 participants

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

Ian McGowan

NCT01575418

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 1
Phase 4 2

Named interventions

Most-linked intervention names on HIV Prevention records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Control Behavioral
2 trials
HEC placebo gel applicators Other
1 trials
iENGAGE for PrEP Behavioral
1 trials
DOT Diary mobile app Other
1 trials
Emtricitabine / Tenofovir Disoproxil Oral Tablet Drug
1 trials
Radiolabeling of study drugs and semen Radiation
1 trials
Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel Drug
1 trials
Vaginal formulation (VF) of tenofovir 1% gel Drug
1 trials

US sites by state

Facility locations filed on HIV Prevention trials. A trial with sites in several states counts in each.

California 7 trials
Maryland 5 trials
Texas 4 trials
New York 4 trials
North Carolina 3 trials
Florida 3 trials
Washington 2 trials
Rhode Island 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this HIV Prevention page

33 registered trials, 20 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV Prevention condition card totals 33 registered trials; most-linked intervention Control; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.